佛仁制药品牌怎么样 申请店铺

我要投票 佛仁制药在医疗器械行业中的票数:273 更新时间:2025-06-30
佛仁制药是哪个国家的品牌?「佛仁制药」是 甘肃佛仁制药科技有限公司 旗下著名品牌。该品牌发源于陇南市,由创始人曹明月在2004-03-29期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力佛仁制药品牌出海!将品牌入驻外推网,定制佛仁制药品牌推广信息,可以显著提高佛仁制药产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

佛仁制药怎么样

甘肃佛仁制药科技有限公司是在收购原甘肃武都制药厂的基础上重新组建的一家股份制企业,主要利用地方特色药材资源,从事中成药产品的生产经营,有40多年的生产历史。2010年1月再次通过了国家GMP认证,是药品生产国家GMP认证企业。具有“国药准字”批准文号的产品46个,其中14个品种是2009年国家新选定的国家基本药物。

公司座落于陇南市武都工业园区,占地面积为43亩,建筑面积为5800平方米,总投资为2745万元,形成固定资产投资1120万元。建有中药材前处理、中药提取、综合制剂和动力维修四个车间,拥有片剂、丸剂、颗粒剂、散剂四条生产线。再建的生产线有胶囊剂、糖浆剂、酊剂、煎膏剂、流浸膏剂,以及中药饮片车间。

安装有35000m3/h风量的空气净化装置,总体净化级别达到了10万级,高出了国家要求。设有新产品开发研究所和产品检验质保中心。公司整体生产设备齐全,检验仪器齐全。年具有生产丸剂1000吨(大蜜丸500吨、水丸320吨、浓缩丸180吨),片剂4亿片、颗粒剂2000万袋、散剂300万袋的生产能力。

企业组织机构健全,人员结构合理。现有职工96人,各类专业技术人员占员工总数的28%。企业通过不断的技术改造,采取新工艺,购置新设备,在努力提高产品质量的同时,以务实诚信为经营理念,企业品牌的建设和产品影响力已初具规模,公司为了更及时快捷的给客户提供服务,特在郑州设立全国营销中心,面向全国进行推广,产品遍及全国各地30多个省市。2013年实现销售收入3000多万元,上缴税金200多万元,预计2014年销售收入可达近5000万元,利税在420万元以上。

甘肃佛仁制药科技有限公司无论是产品的技术优势还是市场优势,都具有广阔的发展前景。我们会把可持续发展战略相关产业链上的工作和包括环境保护在内的各项工作做的更好,为推动地方中药材持续发展,带动药农脱贫致富,解决下岗职工再就业,为人类社会和经济的发展做出应有的贡献。


Gansu Furen pharmaceutical science and Technology Co., Ltd. is a joint-stock enterprise re established on the basis of the acquisition of the former Gansu Wudu pharmaceutical factory. It mainly uses local characteristic medicinal materials resources to engage in the production and operation of Chinese patent medicine products, with a production history of more than 40 years. In January 2010, it passed the national GMP certification again, and is a national GMP certification enterprise for drug production. There are 46 products with the approval number of "Guoyao Zhunzi", 14 of which are national essential drugs newly selected by the state in 2009. The company is located in Wudu Industrial Park, Longnan City, covering an area of 43 mu, a building area of 5800 square meters, with a total investment of 27.45 million yuan, forming a fixed asset investment of 11.2 million yuan. There are four workshops for Chinese medicine pretreatment, Chinese medicine extraction, comprehensive preparation and power maintenance, and four production lines for tablets, pills, granules and powders. The newly built production lines include capsule, syrup, tincture, decocting agent, liquid extract, and herbal pieces workshop. The air purification device with 35000m3 / h air volume is installed, and the overall purification level has reached 100000, which is higher than the national requirements. There are new product development research institute and product inspection and Quality Assurance Center. The company has complete production equipment and inspection instruments. The annual production capacity is 1000 tons of pills (500 tons of honey pills, 320 tons of water pills and 180 tons of concentrated pills), 400 million tablets, 20 million bags of granules and 3 million bags of powder. The organizational structure of the enterprise is sound and the personnel structure is reasonable. At present, there are 96 employees, 28% of which are professional technicians. Through continuous technological transformation, adopting new technology and purchasing new equipment, while striving to improve the quality of products, the company has established a national marketing center in Zhengzhou to provide services to customers in a more timely and efficient manner, with pragmatic and honest business philosophy, and its brand building and product influence has taken shape. Its products are spread all over the country Multiple provinces and cities. In 2013, the company realized sales revenue of more than 30 million yuan and paid taxes of more than 2 million yuan. It is estimated that in 2014, the sales revenue will reach nearly 50 million yuan and the profit and tax will be more than 4.2 million yuan. Gansu Furen pharmaceutical science and Technology Co., Ltd. has broad prospects for development, both in terms of technical advantages and market advantages. We will do a better job in the industry chain related to the sustainable development strategy and in various works including environmental protection, in order to promote the sustainable development of local traditional Chinese medicine, drive pharmaceutical farmers out of poverty and become rich, solve the problem of reemployment of laid-off workers, and make due contributions to the development of human society and economy.

本文链接: https://brand.waitui.com/559930f52.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

成都先导:终止收购南京海纳医药科技约65%股权事项

成都先导公告,公司原拟以现金方式受让股权的方式合计取得南京海纳医药科技股份有限公司约65%的股权。《股权收购意向书》签署后,公司积极组织交易各方推进本次交易,聘请了专业的中介机构对标的公司展开尽调,在此基础上,交易各方对本次交易方案进行多次论证和协商,但未能就本次交易事项的核心条款达成一致意见。 为切实维护公司及全体股东利益,经公司充分审慎研究并与交易对方友好协商,交易各方一致同意终止本次交易事项,本次重大资产重组事项终止。

2小时前

磁谷科技股东宝利丰拟减持,不超过总股本3%

6月29日,磁谷科技公告显示,股东南京宝利丰创业投资合伙企业(有限合伙)因自身资金安排,拟通过集中竞价、大宗交易的方式减持其持有的公司股份不超过2,149,569股。减持不超过公司总股本的3.00%。

2小时前

中信证券:中报季还是以结构性机会为主,预计AI和军工是三季度寻找结构性机会的重心

近日,中信证券研报指出,从板块轮动来看,活跃资金或正从医药和消费切向科技和金融,红利也开始滞涨。结构性机会仍料将是贯穿中报季的话题,指数型机会可能还需要等三季度末到四季度。预计AI和军工是三季度寻找结构性机会的重心。(财联社)

2小时前

*ST金刚:孙公司金刚数智签订3.99亿元重大算力销售合同

6月29日,*ST金刚发布公告称,公司下属孙公司北京金刚数海智算科技有限公司(简称“金刚数智”)于2025年6月27日与江苏***大数据有限公司(简称“算力客户”)签订了《智算中心多元算力服务项目之服务协议》。由金刚数智向算力客户提供算力服务,合同含税总金额3.99亿元,服务期限5年,按月度支付算力服务费用。

2小时前

紫光国微:6月27日以4961.73万元回购77.55万股公司股份

6月29日,紫光国微发布公告称,6月27日公司通过股份回购专用证券账户以集中竞价交易方式实施了首次回购(以下简称“本次回购”)。回购公司股份数量77.55万股,约占公司目前总股本的0.09%,最高成交价为64.28元/股,最低成交价为63.67元/股,成交金额为4961.73万元(不含交易费用)。本次回购资金来源为公司自有资金,回购价格未超过前述回购公司股份方案的规定。

2小时前

本页详细列出关于佛仁制药的品牌信息,含品牌所属公司介绍,佛仁制药所处行业的品牌地位及优势。
咨询